AstraZeneca’s Roxadustat And The Challenge Of Shifting Medicare Coverage Policy
Though the policy environment can be 'uncertain,' AstraZeneca has 'good grasp' on how the anemia drug for patients with chronic kidney disease will be covered under the Medicare end-stage renal disease bundled payment system, senior VP for market access Rick Suarez says.
You may also be interested in...
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.
Amgen ‘looks forward’ to working with CMS and Congress to shape Medicare reimbursement policies in a way that better ensures access.
The Swiss company has been talking up its therapy for elevated levels of potassium in the blood which contributed to strong sales growth for Vifor in 2019.